Dimerix Ltd (ASX:DXB) Share Price

Company Profile

Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUS
T: +61 1300813321
https://www.dimerix.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	61.30	-0.67%
CAC 40	7,929.31	74.70	0.95%
DAX 40	23,778.97	104.44	0.44%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,236.55	8.44	0.09%
HKSE	26,545.10	106.59	0.40%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,045.81	143.54	0.32%
NZX 50 Index	13,231.66	3.23	-0.02%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,773.50	75.00	-0.85%
SSE Composite Index	3,820.09	11.57	-0.30%